Organ Failure Due to Systemic Injury in Acute Pancreatitis
Pramod Kumar Garg,Vijay P. Singh +1 more
Reads0
Chats0
TLDR
The current understanding of the risk factors, pathophysiology, timing, impact on outcome, and therapy of organ failure in acute pancreatitis is reviewed and the distinctions between markers and mediators of severity are highlighted based on evidence supporting their causality in organ failure.About:
This article is published in Gastroenterology.The article was published on 2019-05-01 and is currently open access. It has received 222 citations till now. The article focuses on the topics: Acute pancreatitis & Systemic inflammatory response syndrome.read more
Citations
More filters
Journal Article
Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Commentary
Juhani Sand,Isto Nordback,Marc G. Besselink,Hjalmar C. van Santvoort,Erik Buskens,Marja A. Boermeester,Harry van Goor,Harro M. Timmerman,Vincent B. Nieuwenhuijs,Thomas L. Bollen,Bert van Ramshorst,Ben J.M. Witteman,Camiel Rosman,Rutger J. Ploeg,Menno A. Blink,Alexander F. Schaapherder,Cornelis H. C. Dejong,Peter J. Wahab,Ceesj H. M. Van Laarhoven,Erwin van der Harst,Casper H.J. van Eijck,Miguel A. Cuesta,Louis M. A. Akkermans,Hein G. Gooszen +23 more
TL;DR: In this article, the effects of probiotic prophylaxis in patients with predicted severe acute pancreatitis were evaluated in a multicentre randomised, double-blind, placebo-controlled trial.
Journal Article
The early prediction of mortality in acute pancreatitis : a large population-based study. Commentary
Peter Layer,Bechien U. Wu,Richard S. Johannes,Xiaowu Sun,Ying P. Tabak,Darwin L. Conwell,Peter A. Banks +6 more
TL;DR: In this article, a clinical scoring system was developed for prediction of in-hospital mortality in acute pancreatitis using Classification and Regression Tree (CART) analysis, which was derived on data collected from 17 992 cases of AP from 212 hospitals in 2000-2001.
Journal ArticleDOI
Pancreatic triglyceride lipase mediates lipotoxic systemic inflammation
Cristiane de Oliveira,Biswajit Khatua,Pawan Noel,Sergiy Kostenko,Arup Bag,Bijinu Balakrishnan,Krutika Patel,Andre Guerra,Melissa N. Martinez,Shubham Trivedi,Ann E. McCullough,Dora Lam-Himlin,Sarah Navina,Douglas O. Faigel,Norio Fukami,Rahul Pannala,Anna E. Phillips,Georgios I. Papachristou,Erin E. Kershaw,Mark E. Lowe,Vijay P. Singh +20 more
TL;DR: During pancreatitis, obese PNLIP knockout mice, unlike obese adipocyte-specific ATGL knockouts, had lower visceral adipose tissue lipolysis, milder inflammation, lesser organ failure, and improved survival, and thereby worsen organ failure.
Journal ArticleDOI
Critical thresholds: key to unlocking the door to the prevention and specific treatments for acute pancreatitis.
Savio G. Barreto,Aida Habtezion,Anna S. Gukovskaya,Aurelia Lugea,Christie Y. Jeon,Dhiraj Yadav,Péter Hegyi,Viktória Venglovecz,Robert Sutton,Stephen J. Pandol +9 more
TL;DR: This manuscript provides a state-of-the-art review of current understanding of the pathophysiology of AP providing insights into the unanswered clinical questions and presents testable hypotheses aimed at halting progression of severity for the development of effective treatments for this common unpredictable disease.
Journal ArticleDOI
Tetrahedral Framework Nucleic Acids Can Alleviate Taurocholate-Induced Severe Acute Pancreatitis and Its Subsequent Multiorgan Injury in Mice.
TL;DR: It is demonstrated that tetrahedral framework nucleic acids could both alleviate SAP and its subsequent multiorgan injury in mice, thus offering a novel and effective option to deal with SAP in the future.
References
More filters
Journal ArticleDOI
Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis
Roger C. Bone,Robert A. Balk,F. B. Cerra,R. P. Dellinger,A. M. Fein,William A. Knaus,Roland M. H. Schein,W. J. Sibbald +7 more
TL;DR: An American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference was held in Northbrook in August 1991 with the goal of agreeing on a set of definitions that could be applied to patients with sepsis and its sequelae as mentioned in this paper.
Journal ArticleDOI
The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta.
TL;DR: In this article, the inflammasome is identified as a caspase-activating complex that comprises caspases-1, casp-5, Pycard/Asc, and NALP1, a Pyrin domain-containing protein sharing structural homology with NODs.
Journal ArticleDOI
Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus
Peter A. Banks,Thomas L. Bollen,Christos Dervenis,Hein G. Gooszen,Colin D. Johnson,Michael G. Sarr,Gregory G. Tsiotos,Santhi Swaroop Vege +7 more
TL;DR: This international, web-based consensus provides clear definitions to classify acute pancreatitis using easily identified clinical and radiologic criteria and should encourage widespread adoption.
Journal ArticleDOI
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
Elizabeta Nemeth,Seth Rivera,Victoria Gabayan,Charlotte Keller,Sarah Taudorf,Bente Klarlund Pedersen,Tomas Ganz +6 more
TL;DR: These studies in human liver cell cultures, mice, and human volunteers indicate that IL-6 is the necessary and sufficient cytokine for the induction of hepcidin during inflammation and that the IL- 6-hepcid in axis is responsible for the hypoferremia of inflammation.
Journal ArticleDOI
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn,Brian G. Feagan,Paul Rutgeerts,Stephen B. Hanauer,Jean-Frederic Colombel,Jean-Frederic Colombel,Bruce E. Sands,Milan Lukas,Richard N. Fedorak,Scott D. Lee,Brian Bressler,I. Fox,Maria Rosario,Serap Sankoh,Jing Xu,Kristin Stephens,Catherine Milch,Asit Parikh +17 more
TL;DR: Vedolizumab-treated patients with active Crohn's disease were more likely than patients receiving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response to induction therapy who continued to receive vedolIZumab (rather than switching to placebo) were morelikely to be in remission at week 52.